Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Fate Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the biopharmaceutical company will earn ($1.67) per share for the year. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.
Other analysts also recently issued reports about the stock. Bank of America raised shares of Fate Therapeutics from an “underperform” rating to a “neutral” rating in a report on Monday, November 18th. Wedbush reaffirmed a “neutral” rating and set a $5.00 price target on shares of Fate Therapeutics in a research note on Tuesday, November 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.75.
Fate Therapeutics Price Performance
FATE stock opened at $1.34 on Wednesday. The firm has a 50 day simple moving average of $1.95 and a two-hundred day simple moving average of $3.00. The stock has a market cap of $152.61 million, a PE ratio of -0.81 and a beta of 2.02. Fate Therapeutics has a one year low of $1.04 and a one year high of $8.83.
Fate Therapeutics (NASDAQ:FATE – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.02. The company had revenue of $3.07 million during the quarter, compared to analyst estimates of $0.88 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%.
Institutional Trading of Fate Therapeutics
A number of institutional investors have recently made changes to their positions in FATE. Institute for Wealth Management LLC. bought a new stake in shares of Fate Therapeutics during the 4th quarter valued at about $110,000. SG Americas Securities LLC raised its stake in Fate Therapeutics by 30.6% during the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 10,511 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Fate Therapeutics by 18.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company’s stock valued at $6,431,000 after purchasing an additional 283,080 shares during the last quarter. Barclays PLC increased its stake in shares of Fate Therapeutics by 245.3% in the 3rd quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company’s stock worth $1,485,000 after purchasing an additional 301,389 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Fate Therapeutics by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company’s stock worth $7,905,000 after acquiring an additional 10,863 shares in the last quarter. Hedge funds and other institutional investors own 97.54% of the company’s stock.
Insider Transactions at Fate Therapeutics
In related news, Director Redmile Group, Llc purchased 397,964 shares of Fate Therapeutics stock in a transaction that occurred on Friday, December 20th. The shares were acquired at an average cost of $1.68 per share, for a total transaction of $668,579.52. Following the transaction, the director now directly owns 12,884,277 shares in the company, valued at $21,645,585.36. The trade was a 3.19 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.00% of the company’s stock.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Featured Stories
- Five stocks we like better than Fate Therapeutics
- How to Read Stock Charts for Beginners
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- What Does Downgrade Mean in Investing?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Retail Stocks Investing, Explained
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.